GlassScriptPhysician profile
Dennis H Kim
NPI 1871763235
$4,566.34
in general payments reported to CMS, 2019-2025
29 companies · $887 in 2025
The $887 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $459 · 2021: $421 · 2022: $629 · 2023: $815 · 2024: $964 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.31 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.88 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $573.36 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Csl Behring | $565.45 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $437.14 | 2020-2025 | |
| Pfizer INC. | $327.13 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $295.13 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $284.11 | 2019-2025 | Trelegy Ellipta, Nucala |
| Novartis Pharmaceuticals Corporation | $223.39 | 2019-2025 | |
| Grifols USA, LLC | $120.20 | 2020-2025 | Xembify |
| Pharming Healthcare, INC. | $111.63 | 2022-2024 | Ruconest |
| Optinose US, INC. | $100.76 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $95.13 | 2023 | Quviviq |
| Biocryst US Sales Co., LLC | $94.16 | 2021-2024 | Orladeyo |
| Amgen INC. | $88.36 | 2022-2025 | Tezspire |
| Octapharma USA, INC. | $75.04 | 2021-2024 | Cutaquig |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.63 | 2019-2024 | Xolair |
| Kaleo, INC. | $61.08 | 2020-2023 | Auvi-Q |
| Incyte Corporation | $55.84 | 2024 | Niktimvo |
| Leo Pharma INC. | $52.52 | 2022 | |
| Alk-Abello, INC | $49.66 | 2022-2023 | Odactra, Grastek, Ragwitek |
| Blueprint Medicines Corporation | $45.87 | 2024 | Ayvakit |
| Shire North American Group INC | $35.00 | 2019 | |
| Aimmune Therapeutics, INC. | $28.09 | 2020-2022 | |
| Abbvie INC. | $25.22 | 2020 | |
| Adma Biomanufacturing LLC | $20.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.65 | 2019 | |
| Galderma Laboratories, L.P. | $14.62 | 2025 | Nemluvio |
| Phadia US INC. | $14.48 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.